Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 5,058 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Inflammation
Interventions: Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo); Dietary Supplement · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 70 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Postoperative Pain
Interventions: Q8003, Morphine sulfate, Oxycodone HCl, Oxycodone HCl 4mg; Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Phoenix, Arizona • Anaheim, California • Owings Mills, Maryland + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: ORMD-0801 8 mg, Placebo capsule, ORMD-0801 16 mg; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: TAK-906; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Barrett Oesophagitis With Dysplasia
Interventions: Itraconazole in capsule form, Itraconazole in solution form; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 21
States / cities: Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more

Conditions: Covid19
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Post-Exercise Hypotension
Interventions: Moderate Intensity Aerobic Exercise; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: High Triglyceride Level, HIV Infection
Interventions: Lovaza; Drug
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Anxiety, Fear, Depression, Anxiety and Fear, Anxiety Disorders, Anxious Depression
Interventions: Lorazepam, Placebo; Drug · Other
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Type 1 Diabetes
Interventions: ORMD-0801 capsules- 2x8mg, ORMD-0801 capsules- 3x8mg, ORMD-0801 capsules- 1x16mg; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Emphysema
Interventions: Losartan, Placebo; Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 40 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 28
States / cities: Birmingham, Alabama • Tucson, Arizona • San Diego, California + 18 more

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab; Drug · Combination Product
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 57
States / cities: Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more

Conditions: Triple Negative Breast Cancer
Interventions: ENMD-2076; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Indianapolis, Indiana

Conditions: Advanced Cancer, Non-Small Cell Lung Cancer
Interventions: MKC-1, pemetrexed; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Seattle, Washington + 1 more

Conditions: Adverse Childhood Experiences, Endothelial Dysfunction
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Maxillary Sinusitis
Interventions: azithromycin SR (Zithromax; compound: CP-62,993), placebo, levofloxacin; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 59
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 37 more

Conditions: Healthy
Interventions: Carbohydrate blocking supplement (CBS), Placebo capsule; Dietary Supplement
Lead sponsor: dōTERRA International; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Clostridioides Difficile Infection
Interventions: CRS3123, Active Comparator; Drug
Lead sponsor: Crestone, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Fullerton, California • Lancaster, California • Mission Hills, California + 14 more

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Cypress, California • Miami Springs, Florida • Durham, North Carolina

Conditions: Vitamin D Deficiency, Rotator Cuff Tears
Interventions: Vitamin D3 supplementation, Placebo; Dietary Supplement · Other
Lead sponsor: Community Memorial Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Ventura, California

Conditions: Healthy
Interventions: Palbociclib Alone, Palbociclib plus itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Arthritis, Rheumatoid
Interventions: valdecoxib, naproxen, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 52
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 46 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 97
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Search by objective public record fields.

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Itraconazole to Prevent Recurrent Barrett's Esophagus

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

Determinants of Changes in Arterial Load Following Exercise

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

Losartan Effects on Emphysema Progression

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer

ACEs, SIRT1, and Premature Vascular Aging in Humans

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults

Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Vitamin D3 Supplementation for Vitamin D Deficiency in Rotator Cuff Repair Surgery

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients